Sarepta Elevidys EU Setback - Search News

Order byBest matchMost fresh

News

EU, Sarepta and Elevidys

· 2d · on MSN

EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' gene therapy Elevidys for a type of rare muscular dystrophy, the health agency said on Friday. Shares of the company were down nearly 17% at $10.

Continue reading

Investing.com South Africa · 2d

Sarepta stock falls after Elevidys fails to get backing by EU regulators

Fierce Pharma · 1d

Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe

4don MSN

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

Sarepta stock fell after it agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular ...

20hon MSN

What’s behind Sarepta’s gene therapy deaths?

Three patient deaths linked to neuromuscular drugs developed by Sarepta Therapeutics (NASDAQ:SRPT) have drawn regulatory ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results